Report Overview:
Onychomycosis, also known as tinea unguium, is a fungal infection of the nail. Symptoms may include white or yellow nail discoloration, thickening of the nail, and separation of the nail from the nail bed. Toenails or fingernails may be affected, but it is more common for toenails. Complications may include cellulitis of the lower leg. A number of different types of fungus can cause onychomycosis, including dermatophytes and Fusarium. Risk factors include athlete's foot, other nail diseases, exposure to someone with the condition, peripheral vascular disease, and poor immune function. The diagnosis is generally suspected based on the appearance and confirmed by laboratory testing.
This report provides a deep insight into the global Onychomycosis Treatment market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
Market Value:
The global Onychomycosis Treatment market size was estimated at USD 3290 million in 2024 and is projected to reach USD 4298.93 million by 2032, exhibiting a CAGR of 3.40% during the forecast period.
North America Onychomycosis Treatment market size was estimated at USD 907.98 million in 2024, at a CAGR of 2.91% during the forecast period of 2025 through 2032.
CAGR of 3.40% (2025 – 2032)
By Types:
Oral Medicine
External Medicine
By Applications:
Key players include:
•Johnson & Johnson
•GSK
•Novartis
•Pfizer
•Bausch Health
•Kaken Pharmaceutical
•Galderma
•Bayer
•Lumenis
•Moberg Pharma
•Including or Excluding key companies relevant to your analysis.
